Cryo Cell International Inc Stock: price and insider trades · United States

From a competitive standpoint, Cryo-Cell is a specialized niche player in regenerative medicine infrastructure rather than a broad biotech developer. Its differentiation comes from its early-market heritage, installed specimen base, regulatory and quality credentials, and intellectual-property-backed processing technology. In its most recent filings, the company states that it stores more than 250,000 cord blood and cord tissue specimens worldwide. That scale does not place it among large-cap healthcare firms, but it does support a long-duration, recurring-storage-service model with meaningful brand and trust components.([sec.gov](https://www.sec.gov/Archives/edgar/data/862692/000119312526083096/ccel-20251130.htm?utm_source=openai))

Historically, Cryo-Cell has tried to expand beyond a pure storage business into adjacent therapeutic and manufacturing opportunities. Its SEC filings describe an intended three-part strategy: the legacy cord-blood storage franchise, cord blood and cord tissue infusion clinic services, and, if biologics license approvals were obtained, biopharmaceutical manufacturing. The company also references licensing and research arrangements tied to cord-blood and cord-tissue therapies, although these initiatives have faced execution and legal complexity.([sec.gov](https://www.sec.gov/Archives/edgar/data/862692/000119312526083096/ccel-20251130.htm?utm_source=openai))

Geographically, the operating footprint remains primarily U.S.-centered, but Cryo-Cell also has licensing agreements for marketing its umbilical cord blood stem-cell programs in several Central American countries, including Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, and Panama. That gives the business some international reach, though the company remains fundamentally anchored in the United States market.([sec.gov](https://www.sec.gov/Archives/edgar/data/862692/000119312525240385/ccel-20250831.htm?utm_source=openai))

A major recent development came in 2025–2026: Duke University terminated the company’s patent and technology license agreement in May 2025, and in March 2026 Cryo-Cell disclosed a NYSE American non-compliance notice tied to shareholders’ deficit and recent losses. On May 8, 2026, the exchange accepted the company’s compliance plan and granted a period through September 9, 2027 to regain compliance. For investors, this makes CCEL a specialty healthcare story with long-term niche positioning, but also with elevated financial and listing-risk considerations.([sec.gov](https://www.sec.gov/Archives/edgar/data/862692/000095017025076433/ccel-20250517.htm?utm_source=openai))